Awards & Advancement

Translate Bio appoints Ann Barbier as Chief Medical Officer

Monday, November 6, 2017

Translate Bio, a biotechnology company focused on pioneering the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases, announced the appointment of Ann Barbier, M.D., Ph.D., as chief medical officer, effective immediately. Dr. Barbier brings nearly 20 years of drug discovery and development experience to Translate Bio, and will be responsible for leading all clinical research and development, medical affairs and related functions at Translate Bio.

[Read More]

OCT tops the list of the leading CROs in 3Q 2017

Thursday, November 2, 2017

According to the Synergy Research Group report, the most active CRO in the region were OCT, Quintiles, PSI, Synergy Research Group and IPHARMA. OCT has been working with the largest number of patients during this period. AbbVie tops the list of the leaders among foreign pharmaceutical companies, which initiated clinical trials in 3Q, while Biocad and Severnaya Zvezda were named the most active among Russian companies.

[Read More]

John Potthoff joins SynteractHCR board of directors

Thursday, October 26, 2017

SynteractHCR, a full-service CRO, announced the appointment of industry veteran John Potthoff to its Board of Directors, effective immediately. Potthoff draws on extensive operational, business development and leadership experience derived through his 25-year career dedicated to clinical development.

[Read More]

ERT support for new drug development exceeds 10,000 studies

Thursday, October 26, 2017

ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, has reached a significant milestone in its nearly 50 year history: Global biopharmaceutical companies and CROs have relied on the company to accelerate their clinical development timelines in more than 10,000 studies worldwide.

[Read More]

MTPConnect funds Certara-Monash University program

Thursday, October 26, 2017

MTPConnect (the Medical Technologies and Pharmaceuticals Industry Growth Centre) will provide a proposed AUD750,000 provisional funding to the CertaraMonash University Industry Fellowship Program over two years, with proposed matched funding of AUD750,000 coming from Certara. Together, this funding will allow the Certara-Monash University Industry Fellowship Program to identify and develop the next generation of industry-experienced drug development scientists through training in clinical pharmacology, pharmacometrics and regulatory science to help shape the future and sustainability of the medical research sector in Australia. The program will be located at Monash University Faculty of Pharmacy and Pharmaceutical Sciences and will involve a combination of academic coursework, hands-on industry training, international industry/academic placements and research.

[Read More]